BioSpace News Archive

This New Drug OmepraCare™ is Indicated for the Treatment of Frequent Heartburn and is Expected to add Significant Revenue to the Company

Medtec China 2019 will be held at Shanghai World Expo Exhibition and Convention Center September 25–27.

Immunic, Inc. announced that Hella Kohlhof, Ph.D., Chief Scientific Officer of Immunic, will present newly available preclinical data confirming IMU-935 as a highly potent inhibitor of both, RORt and dihydroorotate dehydrogenase, which was shown to lead to a strong synergism on the reduction of pro-inflammatory cytokine release.

Sage Therapeutics announced that the Company will present at the Goldman Sachs 40th Annual Global Healthcare Conference on Tuesday, June 11, 2019 at 8:00 a.m. PDT in Palos Verdes, Cal.

CollPlant, a regenerative medicine company, announced that the results from a clinical study conducted with its VergenixFG advanced wound care product will be presented at the 29th Conference of the European Wound Management Association.

Multi-center Phase 2 clinical trial on track to initiate in the second half of 2019

Aimmune Therapeutics, Inc. announced results from ARC004, an open-label, rollover study of the landmark Phase 3 PALISADE trial, which showed that extending daily therapy with AR101 by an additional 28 weeks led to improved tolerability with lower numbers of adverse events compared to the PALISADE therapeutic dosing period, an increase in the amount of peanut that could be safely ingested, and continued immunomodulation to peanut protein in most patients.

Platelet BioGenesis announced the addition of Dr. Richard Murray, president and CEO of Jounce Therapeutics, to its board of directors.

Contributing to both the Cancer and Inflammation and Immunity Steering Committees